Drugs / PBF-1650
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03798236 | Dec 2018 → Mar 2019 | psoriasis | Palobiofarma SL | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2019-01-25 | Palo Biofarma, S.L | Palobiofarma has started the clinical development of PBF-1650 palobiofarma.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PBF-1650 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03798236 ↗ |
| Action | Inhibit | “Adenosine A3 receptor (AA3R) antagonist” NCT03798236 ↗ |
| Route | Oral | “PBF-1650 will be administered as single oral ascending- dose” NCT03798236 ↗ |